uniQure N.V. (QURE) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-03-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-03-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-03-31..
Borrowing debt
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 49.94M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 778.71M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | (m) | (m) | $49.94M | (m) | (m) | $778.71M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $49.70M | (m) | (m) | $824.91M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $51.88M | (m) | (m) | $888.38M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $51.84M | (m) | (m) | $584.89M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $51.59M | (m) | (m) | $605.40M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $51.32M | (m) | (m) | $556.54M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $51.11M | (m) | (m) | $645.81M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $102.51M | (m) | (m) | $730.85M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $102.12M | (m) | (m) | $770.05M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $101.75M | (m) | (m) | $831.69M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $101.43M | (m) | (m) | $871.55M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $101.11M | (m) | (m) | $942.77M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $103.25M | (m) | (m) | $631.00M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $102.79M | (m) | (m) | $704.96M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $102.39M | (m) | (m) | $638.23M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $101.89M | (m) | (m) | $701.21M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $101.42M | (m) | (m) | $757.15M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $100.96M | (m) | (m) | $809.18M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $71.49M | (m) | (m) | $774.63M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $70.78M | (m) | (m) | $784.26M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $70.47M | (m) | (m) | $363.85M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $35.62M | (m) | (m) | $340.39M | (m) |
| 2020-09-30 | (m) | (m) | (m) | $35.49M | (m) | (m) | $350.51M | (m) |
| 2020-06-30 | (m) | (m) | (m) | $35.37M | (m) | (m) | $385.34M | (m) |
| 2020-03-31 | (m) | (m) | (m) | $36.21M | (m) | (m) | $414.24M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $36.06M | (m) | (m) | $448.63M | (m) |
| 2019-09-30 | (m) | (m) | (m) | $35.93M | (m) | (m) | $471.59M | (m) |
| 2019-06-30 | (m) | (m) | (m) | $35.78M | (m) | (m) | $253.08M | (m) |
| 2019-03-31 | (m) | (m) | (m) | $35.63M | (m) | (m) | $268.99M | (m) |
| 2018-12-31 | (m) | (m) | (m) | $35.47M | (m) | (m) | $273.91M | (m) |
| 2018-09-30 | (m) | (m) | $11.11M | $9.60M | (m) | (m) | $281.06M | (m) |
| 2018-06-30 | (m) | (m) | $8.03M | $12.84M | (m) | (m) | $308.54M | (m) |
| 2018-03-31 | (m) | (m) | $4.44M | $16.37M | (m) | (m) | $192.24M | (m) |
| 2017-12-31 | (m) | (m) | $1.05M | $19.74M | (m) | (m) | $209.64M | (m) |
| 2017-09-30 | (m) | (m) | $6.23M | $14.35M | (m) | (m) | $138.99M | (m) |
| 2017-06-30 | (m) | (m) | $4.32M | $16.15M | (m) | (m) | $157.97M | (m) |
| 2017-03-31 | (m) | (m) | $2.44M | $17.92M | (m) | (m) | $169.63M | (m) |
| 2016-12-31 | (m) | (m) | $605.00K | $19.63M | (m) | (m) | $190.26M | (m) |
| 2015-12-31 | (m) | (m) | $5.58M | $14.63M | (m) | (m) | $262.66M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |